Cytokinetics Plans Phase I/II Trial Of Ispinesib In First-Line Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Plan for the early stage program is announced simultaneously with disappointing outcomes from three mid-stage trials in various oncology settings.
You may also be interested in...
Cytokinetics Starts Heart-Failure Phase IIa
With its second study, the firm “turns a corner” on enrollment problems.
Cytokinetics Starts Heart-Failure Phase IIa
With its second study, the firm “turns a corner” on enrollment problems.
As Amgen Waits, Cytokinetics Ends Year With Cash Aplenty For Heart Trial
CK-542 center stage for now; ispinesib strategy includes chemo-naive patients.